论文部分内容阅读
目的:观察TP方案(紫杉醇+顺铂)和NP方案(长春瑞滨+顺铂)治疗晚期非小细胞肺癌(NSCLC)的近期疗效及毒副反应。方法:使用TP方案治疗晚期NSCLC 32例,给予紫杉醇(PTX)135mg/m2,静脉滴入,d1;顺铂(DDP)25mg/m2,静脉滴入,d1～d3。使用NP方案治疗晚期NSCLC 33例,给予长春瑞滨(NVB)25mg/m2,静脉滴入,d1,d8;DDP用法同TP方案。每3周重复,2个周期化疗后观察疗效。结果:TP方案有效率为40.6%(13/32),其中腺癌为50%(9/18),鳞癌为33.3%(4/12);NP方案有效率为39.4%(13/33),其中腺癌为35%(7/20),鳞癌为50%(5/10)。骨髓抑制及消化道反应为两者主要毒副反应,白细胞、血小板及血红蛋白减少率分别为93.8%(30/32)、37.5%(12/32)、37.5%(12/32)和75.8%(25/33)、18.2%(6/33)、42.4%(14/33);恶心、呕吐发生率分别为75.0%(24/32)和72.7%(24/33),两者差异无统计学意义。结论:TP和NP方案治疗晚期NSCLC效果均较好,但TP方案对腺癌疗效比NP方案更有优势,NP方案对鳞癌更有优势。
Objective: To observe the short-term curative effect and toxicity of TP regimen (paclitaxel + cisplatin) and NP regimen (vinorelbine + cisplatin) in the treatment of advanced non-small cell lung cancer (NSCLC). Methods: Thirty-two patients with advanced NSCLC were treated with TP regimen. The patients were given paclitaxel (PTX) 135mg / m2 intravenously, d1 and 25mg / m2 cisplatin intravenously for d1 ~ d3. 33 cases of advanced NSCLC were treated with NP regimen, and 25 mg / m2 of vinorelbine (NVB) were given intravenously, d1 and d8. Repeat every 3 weeks, 2 cycles after chemotherapy to observe the effect. Results: The effective rate of TP was 40.6% (13/32), of which 50% (9/18) for adenocarcinoma and 33.3% (4/12) for squamous cell carcinoma; the effective rate of NP was 39.4% (13/33) , Of which adenocarcinoma was 35% (7/20) and squamous cell carcinoma was 50% (5/10). Myelosuppression and digestive tract reaction were the main toxicities and side effects. The reduction rates of white blood cells, platelets and hemoglobin were 93.8% (30/32), 37.5% (12/32), 37.5% (12/32) and 75.8% The incidence rates of nausea and vomiting were 75.0% (24/32) and 72.7% (24/33) respectively, with no statistical difference between the two groups significance. Conclusion: TP and NP regimens are effective in treating advanced NSCLC. However, TP regimen has more advantages than NP regimen in treating adenocarcinoma and NP regimen has more advantages than squamous cell carcinoma.